Dr Richard Kelwick is a recent Royal Society of Edinburgh Enterprise Fellow and an entrepreneurially driven researcher, at Imperial College London, with expertise in both cancer biology and synthetic biology.
Dr Kelwick has a Ph.D. in cancer biology (Prof. Dylan Edwards group, UEA), during which he researched the protective roles of metalloproteinases in cancer. His research led to mechanistic insights into the protective roles of a disintegrin-like and metalloprotease with thrombospondin type motif 15 (ADAMTS15) in breast cancer. Upon moving to Imperial in 2013, Dr Kelwick joined Prof. Paul Freemont’s group (Section of Structural and Synthetic Biology) where he developed expertise in cell-free synthetic biology. In particular, he generated several microbial and mammalian cell-free transcription-translation systems for cell-free biologics and biomaterials production. Moving forward, Dr Kelwick aims to apply his expertise in both cancer biology and synthetic biology towards the development of novel extracellular vesicle (EV) biosensors and isolation methods.
>Successful grant applications (>£400k) Lead or co-applicant: SynbiCITE PoC (2015), Imperial Confidence in Concept Award (2018), BBSRC Pathfinder (2019), Impact Accelerator Account (2019), CRUK Imperial Centre Development Fund (2020) and BBSRC Follow-on-Fund (2020).
>Member of Imperial Postdocs and Fellows Enterprise Network (IPFEN) Committee
>Successful entries in several business competitions (e.g. Techcelerate 2018, OneStart 2016 and Lean Launchpad 2015 with Steve Blank and Jerome Engel). Also, founding president of the UEA Enterprise and Engagement Club [2010 - 2012].
>Author of 12 peer reviewed publications that span my research interests in synthetic biology, cancer biology and EV biology.
>External speaker at University of Cambridge, University of Oxford, several Kenyan research institutions, and at national and international scientific conferences (e.g. UKEV 2019, IET 2016, ECCSB 2017 [Switzerland]).
>A passion for science communication and public engagement. Interviewed on Persian TV (Manoto 1). Organised or supported events in the Science Museum, V&A museum, Tate Modern, Google London Campus, the Imperial Festival [2016; 2017] and at Harris City Academy Crystal Palace. Advisor of several iGEM teams.
et al., 2021, AL-PHA beads: bioplastic-based protease biosensors for global health applications, Materials Today, Vol:in press, ISSN:1369-7021
Kelwick R, Webb A, Freemont P, 2020, Biological materials: the next frontier for cell-free synthetic biology, Frontiers in Bioengineering and Biotechnology, Vol:8, ISSN:2296-4185
et al., 2019, Cell-free prototyping strategies for enhancing the sustainable production of polyhydroxyalkanoates bioplastics, Synthetic Biology, Vol:3, ISSN:2397-7000
Webb AJ, Kelwick R, Freemont PS, 2017, Opportunities for applying whole-cell bioreporters towards parasite detection, Microbial Biotechnology, Vol:10, ISSN:1751-7915, Pages:244-249
et al., 2016, A protease-based biosensor for the detection of schistosome cercariae, Scientific Reports, Vol:6, ISSN:2045-2322
et al., 2015, The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family., Genome Biology, Vol:16, ISSN:1474-760X, Pages:113-113
et al., 2019, AL-PHA beads: bioplastic-bsaed protease biosensors for global health, British Society for Parasitology Autumn Symposium, Belfast, UK
et al., 2019, ISEV2019 Abstract Book. PT09.10: Protease biomarker detection using functionalised bioplastic-based biosensors, ISEV 2019, Co-Action Publishing, ISSN:2001-3078
et al., 2019, SPECIFIC NUCLEIC ACIDS LIGATION FOR DETECTION OF SCHISTOSOMES: SNAILS, 68th Annual Meeting of the American-Society-for-Tropical-Medicine-and-Hygiene (ASTMH), AMER SOC TROP MED & HYGIENE, Pages:182-182, ISSN:0002-9637
et al., 2018, Protease-based bioreporters for the detection of schistosome cercariae, American Society of Tropical Medicine and Hygiene (ASTMH) 67th Annual Meeting, New Orleans, Louisiana, USA
Kelwick R, The role of A Disintegrin and Metalloproteinase with Thrombospondin Motifs-15 (ADAMTS-15) in Breast Cancer